RB

Raj Bardhan

Active Director Director DIN 11873849
DIN 11873849 First appointment Aug 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Raj Bardhan

Raj Bardhan is a Director at Biocept Pharma Private Limited (since 2026).

DIN 11873849
Primary Designation Director
First Appointment 05 Aug 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Biocept Pharma Private Limited U46497DL2026PTC469308
Director05 Aug 20262026Active

Board colleagues of Raj Bardhan

NameDINCompanyDesignation
Priya11873850Biocept Pharma Private LimitedDirector
Dimple KumariBiocept Pharma Private LimitedIndividual Subscriber
Harsh RajBiocept Pharma Private LimitedIndividual Subscriber
Rashmi Kumari08991163Biocept Pharma Private LimitedIndividual Subscriber

Directorship timeline

Open interactive timeline →
Biocept Pharma Private Limited
Premium access

Shareholding and investment profile for Raj Bardhan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Raj Bardhan

Raj Bardhan currently holds 1 directorship: Biocept Pharma Private Limited (Director, since 05 Aug 2026).

Raj Bardhan was first appointed on 05 Aug 2026 as Director at Biocept Pharma Private Limited.

The current boards of Raj Bardhan's companies include Priya (Biocept Pharma Private Limited), Dimple Kumari (Biocept Pharma Private Limited), Harsh Raj (Biocept Pharma Private Limited), Rashmi Kumari (Biocept Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available